Europe Continuous Glucose Monitoring Device (CGMD) Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sensors, Transmitters, and Receivers), Application (Type 1 Diabetes and Type 2 D

The Europe Continuous Glucose Monitoring Device (CGMD) Market is poised for significant growth, projected to reach approximately US$ 9,935.2 million by 2031, up from US$ 3,920.3 million in 2024. This growth trajectory indicates a robust compound annual growth rate (CAGR) of 14.4% from 2025 to 2031.

Executive Summary and Market Analysis

The CGMD market in Europe encompasses key countries including Germany, the UK, France, Spain, Italy, and the Rest of Europe. The landscape of continuous glucose monitoring is undergoing a transformative shift, driven by advancements in healthcare policies, technological innovations, and the emergence of non-invasive solutions. This evolution signifies a transition from traditional episodic glucose checks to a more integrated and real-time approach to diabetes management.

In Northern and Central Europe, particularly in Germany and the Nordic countries, statutory health systems have broadened CGM reimbursement policies to include insulin-dependent patients. Germany, which accounts for over 20% of the European CGM market, has established structured clinical pathways that facilitate the initiation of CGM shortly after diabetes treatment begins. The National Health Service (NHS) in England, following NICE recommendations, supports CGM and intermittently scanned flash glucose monitoring for all type 1 diabetics and select type 2 patients. Additionally, innovative models such as virtual wards in the UK and France have introduced CGM-enabled discharge kits, which have proven effective in reducing hospital readmissions and promoting CGM adoption in both inpatient and remote care settings.

The market is also witnessing the rise of integrated devices, such as Medtronic's MiniMed 780G closed-loop system, which combines a disposable CGM sensor with automated insulin delivery. Furthermore, Roche's AI-driven SmartGuide, which predicts hypoglycemia, exemplifies the convergence of CGM technology with predictive analytics and automated insulin delivery systems. In France, the full national reimbursement for Dexcom One for type 2 patients using basal insulin marks a significant milestone in expanding CGM access beyond the traditional type 1 diabetes demographic.

Strategic Insights

Market Segmentation Analysis

The Europe CGMD market is segmented by product, application, testing sites, and end users:

• By Product: The market is divided into Sensors, Transmitters, and Receivers, with Sensors holding the largest market share in 2024.
• By Application: The market is categorized into Type 1 Diabetes and Type 2 Diabetes, where Type 2 Diabetes is expected to dominate the market share in 2024.
• By Testing Sites: The segments include Fingertip Testing and Alternate Site Testing, with Fingertip Testing leading in market share.
• By End User: The market is segmented into Hospitals and Clinics and Self or Homecare, with Self or Homecare being the largest segment in 2024.

>Market Outlook

A significant growth opportunity in the CGM market lies in enhancing accessibility in emerging and underserved regions, where diabetes prevalence is rapidly increasing. Despite the rising incidence of diabetes, access to modern diabetes management tools remains limited in these areas. Humanitarian organizations are beginning to incorporate CGMs into chronic care programs for displaced populations and refugees, particularly those with Type 1 diabetes. CGMs are particularly beneficial in low-resource settings as they reduce the need for frequent finger sticks and facilitate more autonomous diabetes management.

Innovations in low-cost, non-invasive technology, coupled with the expansion of mobile health infrastructure and local manufacturing, are helping to dismantle long-standing barriers to access. For CGM manufacturers, healthcare providers, and digital health companies, investing in scalable, culturally sensitive, and affordable solutions for these populations presents a unique opportunity to expand market share while addressing critical global health equity challenges in chronic disease management.

Country Insights

The CGMD market is further analyzed by country, with Germany leading the market in 2024. Germany's position as a global leader in CGM adoption is supported by its comprehensive statutory health insurance system, progressive reimbursement policies, and the integration of digital health innovations. Since the pivotal 2016 decision by the Federal Joint Committee (G-BA), real-time CGM has been covered by statutory health insurers for patients who meet specific criteria, such as being insulin-dependent and completing structured CGM training.

As of 2022, the prevalence of CGM use among children and adolescents with type 1 diabetes in Germany was reported at 94.9%. The country also ranks third in the number of adults with diabetes, with approximately 6.5 million adults affected in 2024. The affordability of CGMs is enhanced by insurance coverage, with minimal out-of-pocket costs for patients.

Germany's digital health infrastructure, bolstered by the Digital Healthcare Act (DiGA), promotes the integration of CGM data into patient care pathways, further enhancing the reach and effectiveness of CGM technologies. Hospitals in regions like Bavaria and North Rhine-Westphalia are piloting CGM-enhanced monitoring systems, which facilitate remote supervision of glucose metrics, thereby improving patient outcomes. Show more